This trial is active, not recruiting.

Conditions sepsis, sirs
Treatment septicyte lab molecular diagnostic test (non-interventional)
Sponsor Immunexpress
Collaborator Rhode Island Hospital
Start date June 2015
End date April 2016
Trial size 66 participants
Trial identifier NCT02704871, IXP 04-01b


A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective

Primary Outcomes

SeptiCyte® Lab test result versus Retrospective Physician Diagnosis (RPD) result
time frame: 7 days

Secondary Outcomes

SeptiCyte® Lab test result versus test results for other sepsis biomarkes, including leukocytosis, bandemia, & procalcitonin
time frame: 7 days

Eligibility Criteria

Male or female participants from 18 years up to 89 years old.

Inclusion Criteria: 1. 18-89 years old on the day of enrollment. 2. Currently admitted to study designated medical or surgical ward 3. Have a clinical suspicion of sepsis as determined by two physicians after identification by hospital screening tool. 4. Screened positive for sepsis, severe sepsis or septic shock using the RISE2 screening tool. 5. Completed SBAR handover (Situation, Background, Assessment, Recommendation) 6. SIRS present as defined by the presence of two or more of the following: - Temperature > 38°C or < 36°C - Heart Rate > 90 beat/min - Tachypnea > 20/min or PaCO2 < 32 mmHg - WBC count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils (bands) Exclusion Criteria: 1. Consent not provided 2. Patients less than 18 years of age, or 90 years of age or older. 3. Patients for which a blood sample could not be taken within 24 hours of a physician first determining a clinical suspicion of sepsis. 4. Patients that are not located in the designated medical or surgical ward associated with the study. 5. Patients listed for "Comfort Measures Only". 6. Less than 2 SIRS criteria 7. Commencement of narrow spectrum directed antibiotics prior to screening.

Additional Information

Official title To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS
Principal investigator Mitchell Levy, MD
Description This study is evaluating a molecular diagnostic device developed to distinguish between sepsis and infection-negative SIRS among critically ill patients. This study is a prospective, non-randomized, non-interventional, observational trial of patients with suspected sepsis in the medical and/or surgical wards. The study is being conducted on two preselected patient care units. All patients identified by a local screening tool undergo physician review. If the suspicion of sepsis is found to be plausible, routine and conventional diagnostic procedures, including: routine bloods, blood culture and specialized tests are conducted. Blood collection for SeptiCyte® Lab and SeptID® is drawn within 6 hours of a positive screen - both use peripheral blood as the clinical sample. The diagnostic performance of the two experimental assays will be compared to Retrospective Physician Diagnosis (RPD), and conventional microbiological culture. The results of SeptiCyte® Lab and SeptID® are not used in any clinical decision-making. This data will be used to analyze the performance of SeptiCyte® Lab according to the endpoint measures.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Immunexpress.